David Owens - 26 Feb 2025 Form 4 Insider Report for Nexalin Technology, Inc. (NXL)

Role
Chief Medical Officer, Director
Signature
/s/ David Owens Name: David Owens, M.D.
Issuer symbol
NXL
Transactions as of
26 Feb 2025
Net transactions value
$0
Form type
4
Filing time
27 Feb 2025, 16:33:38 UTC
Previous filing
05 Feb 2025
Next filing
12 Sep 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NXL Stock Option (right to buy) Award $0 +139,821 $0.000000 139,821 26 Feb 2025 Common Stock 139,821 $0.8940 Direct
transaction NXL Stock Option (right to buy) Award $0 +654,363 +468% $0.000000 794,184 26 Feb 2025 Common Stock 654,363 $0.8940 Direct F1
transaction NXL Stock Option (right to buy) Award $0 +125,000 +16% $0.000000 919,184 26 Feb 2025 Common Stock 125,000 $2.95 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests in three equal annual installments based on the satisfaction of certain performance criteria for each of the annual periods ending June 30, 2024, 2025 and 2026. The performance criteria for the period ending June 30, 2024 were met, resulting in the vesting of options to purchase 218,121 shares.